「サブスタンスP」の版間の差分

ナビゲーションに移動 検索に移動

サブスタンスP (ソースを閲覧)

2015年8月6日 (木) 10:56時点における版

8,603 バイト除去 、 2015年8月6日 (木)
細
編集の要約なし
細編集の要約なし
細編集の要約なし
6行目: 6行目:
</div>
</div>


{{box|text=　サブスタンスP substance P(SP)は、ウマの脳および腸管に存在し、血圧を下降させ、平滑筋を収縮させる物質として、1931年にvon EulerとGaddumによって見出され、1971年に単離された神経ペプチドである。類似の構造を持つペプチドと共に、タキキニンtachykininsと総称される。SPに高親和性を持つNK1受容体を介して、様々な細胞内情報伝達系を活性化し、複数のイオンチャネルを修飾する。SPおよびNK1受容体は、神経細胞だけでなく、末梢の非神経細胞にも発現している。従って痛覚、神経原性炎症、情動、報酬系等、広範囲な生理機能と疾患病態に関与している。}}
英語名：substance P(SP)
 
{{box|text=　サブスタンスPは、ウマの脳および腸管に存在し、血圧を下降させ、平滑筋を収縮させる物質として、1931年にvon EulerとGaddumによって見出され、1971年に単離された神経ペプチドである。類似の構造を持つペプチドと共に、タキキニンtachykininsと総称される。SPに高親和性を持つNK1受容体を介して、様々な細胞内情報伝達系を活性化し、複数のイオンチャネルを修飾する。SPおよびNK1受容体は、神経細胞だけでなく、末梢の非神経細胞にも発現している。従って痛覚、神経原性炎症、情動、報酬系等、広範囲な生理機能と疾患病態に関与している。}}


{{chembox
{{chembox
136行目: 138行目:
== 参考文献 ==
== 参考文献 ==
<references / >
<references / >
1. Otsuka M, Yoshioka K: Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993; 73: 229-308.
2. Suzuki H, Yoshioka K, Yanagisawa M, Urayama O, Kurihara T, Hosoki R, Saito K, Otsuka M: Involvement of enzymatic degradation in the inactivation of tachykinin neurotransmitters in neonatal rat spinal cord. [[Br]] J Pharmacol 1994; 113: 310-316.
3. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW: Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014; 94: 265–301.
4. Nakanishi S: Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123-136.
5. Castagliuolo I, Valenick L, Liu J, Pothoulakis C: [[Epidermal growth factor]] receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 2000; 276: 26545-26550.
6. Kurtz MM, Wang R, Clements MK, Cascieri MA, Austin CP, Cunningham [[Br|BR]], Chicchi GG, Liu Q: Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 2002; 296: 205-212.
7. Page NM, Bell NJ, Gardiner SM, Manyonda IT, Brayley KJ, Strange PG, Lowry PJ: Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci USA 2003; 100: 6245-6250.
8. Patacchini R, Lecci A, Holzer P, Maggi CA: Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004; 25: 1-3.
9. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N: Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994; 347: 249-274.
10. Ding Y-Q, Shigemoto R, Takada M, Ohishi H, Nakanishi S, Mizuno N: Localization of the neuromedin K receptor (NK3) in the central nervous system of the rat. J Comp Neurol 1996; 364: 290-310.
11. Takano K, Yasufuku-Takano J, Kozasa T, Singer WD, Nakajima S, Nakajima Y: Gq/11 and PLC-β1 mediate the substance P-induced inhibition of an inward rectifier K+ channel in brain neurons. J Neurophysiol 1996; 76: 2131-2136.
12. Mitra-Ganguli T, Vitko I, Perez-Reyes E, Rittenhouse [[AR]]: Orientation of palmitoylated CaVβ2a relative to [[Cav2.2|CaV2.2]] is critical for slow pathway modulation of N-type [[CA2|Ca2]]+ current by tachykinin receptor activation. J Gen Physiol 2009; 134: 5385–5396.
13. Shapiro MS, Hille B: Substance P and somatostatin inhibit [[calcium]] channels in rat sympathetic neurons via different G protein pathways. Neuron 1993; 10: 11-20.
14. Talley EM, Lei Q, Sirois JE, Bayliss DA: TASK-1, a two–pore domain K+ channel is modulated by multiple neurotransmitters in motoneurons. Neuron 2000; 25: 399-410.
15. Koizumi H, Smerin SE, Yamanishi T, Moorjani BR, Zhang R, Smith JC: TASK channels contribute to the K+-dominated leak current regulating respiratory rhythm generation in vitro. J Neurosci 2010; 30: 4273-4284.
16. Ptak K, Yamanishi T, Aungst J, Milescu LS, Zhang R, Richerson GB, Smith JC: Raphé neurons stimulate respiratory circuit activity by multiple mechanisms via endogenously released [[serotonin]] and substance P. J Neurosci 2009; 29: 3720-3737.
17. Whittle BJR, Lopez-Belmonte J, Rees DD: Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol 1989; 98: 646-652.
18. Snider WD, McMahon SB: Tackling pain at the source: new ideas about nociceptors. Neuron 1998; 20: 629-632.
19. Guo A, Vulchanova L, Wang J, Li X, Elde R: Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999; 11: 946-958.
20. McLeod AL, Ritchie J, Cuello AC, Julien J-P, Ribeiro-da-Silva A, Henry JL: Transgenic mice over-expressing substance P exhibit allodynia and hyperalgesia which are reversed by substance P and N-methyl-D-aspartate receptor antagonists. Neuroscience 1999; 89: 891-899.
21. Zhang Z, Cang C-L, Kawasaki Y, Liang L-L, Zhang Y-Q, Ji R-R, ZhaoZ-Q: Neurokinin-1 receptor enhances TRPV1 activity in primary sensory neurons via PKCε: a novel pathway for heat hyperalgesia. J Neurosci 2007; 27: 12067-12077.
22. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJH, Laird JMA, Belmonte C, Cervero F, Hunt SP: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998; 392: 394-397.
23. Nitzan-Luques A , Devor M, Tal M: Genotype-selective phenotypic switch in primary afferent neurons contributes to neuropathic pain. Pain 2011; 152: 2413-2426.
24. Suzuki1 R, Morcuende S, Webber M, Hunt SP, Dickenson AH: Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nature Neurosci. 2002; 5: 1319-1326.
25. Muto Y, Sakai A, Sakamoto A, Suzuki H: Activation of NK1 receptors in the [[locus coeruleus]] induces analgesia through noradrenergic-mediated descending inhibition in a rat model of neuropathic pain. Br J Pharmacol 2012; 166: 1047-1057.
26. Chiu IM, von Hehn CA, Woolf CJ: Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nature Neurosci 2012; 15: 1063-1067.
27. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI: Primary afferent tachykinins are required to experience moderate to intense pain. Nature 1998; 392: 390-394.
28. Saito R, Suehiro Y, Ariumi H, Migita K, Hori N, Hashiguchi T, Sakai M, Saeki M, Takano Y, Kamiya H: Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets. Neurosci Lett 1998; 254: 169-172.
29. Diemunsch P, Joshi GP, Brichant JF: Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesthesia 2009; 103: 7-13.
30. de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ: The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004; 40: 403-410.
31. Ebner K, Rupniak NM, Saria A, Singewald N: Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101: 4280-4285.
32. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, et al. : Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
33. Brodin E, Rosén A, Schött E, Brodin K: Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions. Neuropeptides 1994; 26: 253-260.
34. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ: Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 2001; 98: 1912-1917.
35. Murtra P, Sheasby AM, Hunt SP, De Felipe C: Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 2000; 405: 180-183.
36. Barbier E, Vendruscolo LF, Schlosburg JE, Edwards S, Juergens N, Park PE, Misra KK, Cheng K, Rice KC, Schank J, Schulteis G, Koob GF, Heilig M: The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology. 2013; 38: 976-984.
37. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M: Neurokinin 1 receptor antagonism as a possible therapy for alcoholism.  Science 2008; 319: 1536-1539.
38. Saji K, Ikeda Y, Kim W, Shingai Y, Tateno A, Takahashi H, Okubo Y, Fukayama H, Suzuki H: Acute NK₁ receptor antagonist administration affects reward incentive anticipation processing in healthy volunteers. Int J Neuropsychopharmacol 2013; 16: 1461-1471.
39. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, Serin A, Mungan [[NO]], Cook JR, Ozbek MN, Imamoglu S, Akalin NS, Yuksel B, O'Rahilly S, Semple RK: TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nature Genet 2009; 41: 354-358.
40. Skorupskaite K, George JT, Anderson RA: The kisspeptin-GnRH pathway in human reproductive health and disease. Human Reproduction Update 2014; 20: 485-500.
「https://bsd.neuroinf.jp/wiki/特別:携帯機器差分/31249」から取得

案内メニュー